MK-2010 alone or with other treatments for advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2 interventional study evaluating MK-2010 as a standalone treatment and in combination with other therapies for adults with advanced solid tumors. Participants may receive MK-2010 alone or together with pembrolizumab, 5-fluorouracil, leucovorin, or oxaliplatin, depending on the regimen. The study aims to evaluate safety and tolerability, and to see how many participants respond by tumor shrinkage or disappearance. Eligibility requires measurable disease, adequate organ function, and certain health exclusions. The trial is sponsored by Merck Sharp & Dohme and conducted at sites in New Jersey and Ohio.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Has radiographically measurable disease per protocol
* If to receive oral study treatment, has the ability to swallow and retain oral medication and does not have gastrointestinal abnormalities that may alter absorption
* Has well-controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART) if diagnosed with HIV
* Has adequate organ function per protocol

Exclusion Criteria:

* Has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease if diagnosed with HIV
* Has a history of posterior reversible encephalopathy syndrome (PRES) or seizure disorder
* Has hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh class B or more severe liver cirrhosis
* Has a history of confirmed inflammatory bowel disease
* Has a serious active nonhealing wound, ulcer, and/or bone fracture
* Has a history of myocarditis or cardiomyopathy
* Has a history of or current severe cardiovascular and cerebrovascular diseases
* Is currently receiving any anticoagulants
* Has a diagnosis of immunodeficiency
* Has a known additional malignancy that is progressing or required active treatment within the past 3 years
* Has known active central nervous system metastases and/or carcinomatous meningitis
* Has active autoimmune disease that required systemic treatment in the past 2 years (hormonal supplementation \[eg, thyroxine, insulin, or physiologic corticosteroid\] is allowed)
* Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids or has current pneumonitis/ILD
* Has a history of stem cell/solid organ transplant
* Has not adequately recovered from major surgery or from central venous access device placement, or has ongoing surgical complications

Where it's running

• New Jersey Cancer Care ( Site 7002)
  Belleville, New Jersey, United States Recruiting
• START Astera, LLC ( Site 0220)
  East Brunswick, New Jersey, United States Recruiting
• Taylor Cancer Research Center ( Site 9500)
  Maumee, Ohio, United States Recruiting
• Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8001)
  Eugene, Oregon, United States Recruiting
• Princess Margaret Cancer Centre ( Site 1400)
  Toronto, Ontario, Canada Recruiting
• Cantonal Hospital St.Gallen ( Site 1100)
  Sankt Gallen, Canton of St. Gallen, Switzerland Recruiting

Study contacts

• Study coordinator: Toll Free Number
• Email: Trialsites@msd.com
• Phone: 1-888-577-8839

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• AK157D1 injection for advanced solid tumors

  A first-in-human Phase 1 study tests AK157D1 injection in adults with unresectable advanced solid tumors to see if it is safe and tolerable and to get early signs of how it behaves in the body and against tumors.

  Recruiting Phase 1 Akeso · Harbin, Heilongjiang and 2 other locations · NCT07847281

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• Whole-Body Infrared Heating for Advanced Solid Tumors

  This study looks at how ET-SPACE whole-body infrared hyperthermia affects people with advanced solid tumors to see if it changes biology, symptoms, and safety.

  Recruiting Zhejiang Hospital · Hangzhou, Zhejiang · NCT07793214

• MK-2010 with Sac-TMT in advanced solid tumors

  This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.

  Recruiting at 4 sites Phase 2 Merck Sharp & Dohme LLC · San Antonio, Texas and 3 other locations · NCT07785609

• CBX-663 dose-escalation study in adults with relapsed or refractory myeloid cancers, advanced solid tumors, or glioblastoma

  This early-phase trial tests CBX-663 to see if it is safe and tolerable and to get an early sense of activity in adults with relapsed/refractory myeloid cancers, advanced solid tumors, or recurrent glioblastoma.

  Recruiting at 4 sites Phase 1 Crossbow Therapeutics, Inc. · Duarte, California and 3 other locations · NCT07779798

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.